ASND — ASCENDIS PHARMA A S

Ownership history in TWO SIGMA SECURITIES, LLC  ·  6 quarters on record

This page tracks every 13F SEC filing in which TWO SIGMA SECURITIES, LLC reported a position in ASCENDIS PHARMA A S (ASND). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
0.03% (2025 Q3)
Avg. % of fund
0.01%
First filed
2020 Q2
Last filed
2025 Q3
Quarters held
6
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 REDUCED 1,162 -519 -30.9% 0.03% $231K $198.81
2024 Q3 REDUCED 1,681 -194 -10.3% 0.00% $251K $149.31
2024 Q1 REDUCED 1,875 -1,157 -38.2% 0.00% $283K $151.17
2023 Q4 ADDED 3,032 +792 +35.4% 0.00% $382K $125.95
2023 Q1 ADDED 2,240 +812 +56.9% 0.00% $240K $107.22
2020 Q2 INITIATED 1,428 — — 0.00% $211K $147.90
% of Fund (quarterly)    ASND price (monthly, adj. close)

Other funds also holding ASND

As of 2025 Q4 — sorted by position size

Q Global Advisors, LLC 3Y 7Y 39.86% RA CAPITAL MANAGEMENT, L.P. 3Y 7Y 22.46% Avoro Capital Advisors LLC 3Y 7Y 10.71% Resolute Capital Asset Partners LLC 3Y 9.13% Tri Locum Partners LP 3Y 7.34% WESTFIELD CAPITAL MANAGEMENT CO LP 3Y 7Y 4.61% Catalio Capital Management, LP 4.49% Spyglass Capital Management LLC 3Y 7Y 4.43% PERCEPTIVE ADVISORS LLC 3Y 7Y 4.11% PFM Health Sciences, LP 3Y 7Y 3.78%
← Back to TWO SIGMA SECURITIES, LLC Holdings